title: Preliminary evaluation of an in vitro test for assessment of excitotoxicity by measurement of early gene (c-fos mRNA) levels.
abstract: Using primary cultures of mouse cerebellar granule cells as an in vitro model system, it has been demonstrated that different profiles of temporal expression of the c-fos proto-oncogene are observed under non-excitotoxic and excitotoxic conditions. A ratio has been derived previously for the steady-state level of c-fos mRNA after 30 min and 240 min which suggests that a 240 min/30 min ratio of greater than 1 correlates with excitotoxicity, whereas a ratio of less than 1 correlates with a non-excitotoxic outcome. Moreover, a positive correlation is seen with abrogation of excitotoxicity in response to selective excitatory amino acid receptor antagonists. This test, proposed as a specific biomarker for excitotoxicity is undergoing prevalidation. Excitotoxicity is defined as neuronal cell death mediated by hyperactivation of glutamate receptor subtypes and therefore might be expected to be prevented by selective glutamate receptor antagonists. In preliminary evaluation studies, we have conducted work under the direction of the European Center for Validation of Alternate Methods (ECVAM) using compounds specified by ECVAM that have been subdivided into four groups based on known or presumed actions. These groups comprise: Group 1-endogenous/synthetic excitotoxins; Group 2-environmental, putative excitotoxins; Group 3-neurotoxic but non-excitotoxic compounds, and Group 4-non-toxic compounds. The results of this study support the proposal that the c-fos mRNA time-ratio test is a specific biomarker of excitotoxicity. Just as importantly, this test has the potential for application in screening newly-designed EAA receptor antagonists in the search for clinically relevant drugs to treat a variety of neuropathologies.
authors.affiliation: School of Biology, University of St Andrews, Fife KY16 9ST, Scotland, UK. rg3@st-andrews.ac.uk
authors.forename: R
authors.initials: R
authors.lastname: Griffiths
authors.forename: A
authors.initials: A
authors.lastname: Grieve
authors.forename: J
authors.initials: J
authors.lastname: Scollon
authors.forename: M
authors.initials: M
authors.lastname: Scott
authors.forename: C
authors.initials: C
authors.lastname: Williams
authors.forename: C
authors.initials: C
authors.lastname: Meredith
mesh_terms: D000818:Animals; D016923:Cell Death / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002525:Cerebellar Cortex / Q000187:drug effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D018691:Excitatory Amino Acid Antagonists / Q000633:toxicity*; D005786:Gene Expression Regulation; D016762:Genes, fos; D018698:Glutamic Acid / Q000494:pharmacology; D051379:Mice; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D018691:Excitatory Amino Acid Antagonists; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D018698:Glutamic Acid